Choosing ART: What Does the Evidence Say?Premiere Date: Thursday, October 29, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, October 29, 2021
Note: Credit Is No Longer Available
|Monica Gandhi, MD, MPH
Professor of Medicine and Associate Division Chief (Clinical Operations/Education)
Division of HIV, Infectious Diseases, and Global Medicine
University of California San Francisco (UCSF)/San Francisco General Hospital (SFGH)
Director, UCSF Center for AIDS Research (CFAR)
Medical Director, HIV Clinic at SFGH
San Francisco, CA
There have been many recent therapeutic advances in human immunodeficiency virus (HIV), aiming to improve rates of viral suppression, reduce treatment burden, and improve treatment adherence. Current HIV guidelines provide recommendations for managing patients with HIV, including treatment initiation, therapy switching, and individualized treatment regimens for special populations. Rapid antiretroviral therapy (ART) initiation is imperative for early virologic suppression after HIV infection, as it improves health outcomes and decreases transmission. All individuals living with HIV should be offered ART following a confirmed diagnosis, with same-day initiation available. However, despite the benefits of early treatment, ART initiation is often delayed.
This CME Outfitters BriefCase focuses on incorporating the latest evidence-based and guideline-directed treatment strategies for a patient who has been newly diagnosed with HIV.
At the end of this CE activity, participants should be able to:
- Incorporate the latest evidence-based and guideline-directed treatment strategies in the management of patients newly diagnosed with HIV.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Assess the latest evidence-based and guideline-directed treatment strategies in the management of patients newly diagnosed with HIV.
Supported by independent educational grants from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. The supporters were not involved in the development of content or the selection of faculty for this educational activity.
Infectious disease specialists, primary care physicians, PAs, nurse practitioners, nurses, pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gandhi has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).